These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7232848)

  • 1. New natural products under development at the National Cancer Institute.
    Douros J; Suffness M
    Recent Results Cancer Res; 1981; 76():153-75. PubMed ID: 7232848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New natural products of interest under development at the National Cancer Institute.
    Douros J; Suffness M
    Cancer Chemother Pharmacol; 1978; 1(2):91-100. PubMed ID: 86390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo antitumor evaluation of antibiotics. Selected results from the Drug Evaluation Program of the National Cancer Institute, U.S.A.
    Venditti JM; Johnson RK
    Recent Results Cancer Res; 1978; 63():49-57. PubMed ID: 705014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The National Cancer Institute's Natural Products Antineoplastic Development Program.
    Douros J; Suffness M
    Recent Results Cancer Res; 1980; 70():21-44. PubMed ID: 7355247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational drugs under study by the United States National Cancer Institute.
    Carter SK; Slavik M
    Cancer Treat Rev; 1976 Mar; 3(1):43-60. PubMed ID: 62615
    [No Abstract]   [Full Text] [Related]  

  • 6. Antitumor screening procedures of the National Cancer Institute.
    Schepartz SA
    Jpn J Antibiot; 1977 Dec; 30 Suppl():35-40. PubMed ID: 612710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of anticancer agents--a National Cancer Institute perspective.
    Marsoni S; Wittes R
    Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
    [No Abstract]   [Full Text] [Related]  

  • 8. [Models and methods used for the selection of antitumor preparations in the USSR and abroad].
    Sof'ina ZP
    Vopr Onkol; 1976; 22(4):82-96. PubMed ID: 1274284
    [No Abstract]   [Full Text] [Related]  

  • 9. Progress report on the screening program at the Division of Cancer Treatment, National Cancer Institute.
    Goldin A; Venditti JM
    Cancer Treat Rev; 1980 Dec; 7(4):167-76. PubMed ID: 7214373
    [No Abstract]   [Full Text] [Related]  

  • 10. [Introduction of new screening system in National Cancer Institute].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1984 May; 11(5):1134-9. PubMed ID: 6539100
    [No Abstract]   [Full Text] [Related]  

  • 11. Preclinical status of macromomycin at the National Cancer Institute.
    Bono VH; Abraham D
    Recent Results Cancer Res; 1978; 63():113-9. PubMed ID: 705006
    [No Abstract]   [Full Text] [Related]  

  • 12. Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute.
    Goldin A; Venditti JM; Macdonald JS; Muggia FM; Henney JE; Devita VT
    Eur J Cancer (1965); 1981 Feb; 17(2):129-42. PubMed ID: 6894902
    [No Abstract]   [Full Text] [Related]  

  • 13. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective screening program: current screening and its status.
    Goldin A; Venditti JM
    Recent Results Cancer Res; 1981; 76():176-91. PubMed ID: 7232850
    [No Abstract]   [Full Text] [Related]  

  • 15. The new NCI screen and its implications for clinical evaluation.
    Goldin A; Venditti JM
    Recent Results Cancer Res; 1980; 70():5-20. PubMed ID: 7355249
    [No Abstract]   [Full Text] [Related]  

  • 16. New anticancer antibiotics under development and clinical evaluation in the National Cancer Institute.
    Slavik M
    Recent Results Cancer Res; 1978; 63():282-7. PubMed ID: 705012
    [No Abstract]   [Full Text] [Related]  

  • 17. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary.
    Venditti JM
    Cancer Treat Rep; 1983 Sep; 67(9):767-72. PubMed ID: 6883352
    [No Abstract]   [Full Text] [Related]  

  • 18. The evaluation of cytotoxic drugs.
    Von Hoff DD; Rozencweig M; Muggia FM
    Cancer Treat Rev; 1979 Jun; 6 Suppl():1-8. PubMed ID: 498161
    [No Abstract]   [Full Text] [Related]  

  • 19. The National Cancer Institute: cancer drug discovery and development program.
    Grever MR; Schepartz SA; Chabner BA
    Semin Oncol; 1992 Dec; 19(6):622-38. PubMed ID: 1462164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of cancer chemotherapy.
    Chabner BA
    Hosp Pract (Off Ed); 1985 Apr; 20(4):115-9, 123-7. PubMed ID: 3932415
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.